Publicaciones en las que colabora con IGNACIO MARÍN JIMÉNEZ (29)

2024

  1. Controversies in the management of anti-TNF therapy in patients with Crohn's disease: a Delphi consensus

    BMJ Open Gastroenterology, Vol. 11, Núm. 1

2023

  1. Akkermansia deficiency and mucin depletion are implicated in intestinal barrier dysfunction as earlier event in the development of inflammation in interleukin-10-deficient mice

    Frontiers in Microbiology, Vol. 13

  2. Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort

    International Journal of Molecular Sciences, Vol. 24, Núm. 2

  3. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

    Clinical Gastroenterology and Hepatology, Vol. 21, Núm. 3, pp. 771-788.e10

  4. Single nucleotide polymorphisms in ADAM17, IL23R and SLCO1C1 genes protect against infliximab failure in adults with Crohn's disease

    Biomedicine and Pharmacotherapy, Vol. 159

2022

  1. Sphk2 deletion is involved in structural abnormalities and Th17 response but does not aggravate colon inflammation induced by sub-chronic stress

    Scientific Reports, Vol. 12, Núm. 1

2021

  1. Comparison of a new rapid method for determination of serum anti-adalimumab and anti-infliximab antibodies with two established ELISA kits

    Journal of Pharmaceutical and Biomedical Analysis, Vol. 198

  2. Histological inflammatory activity can predict endoscopic relapse in patients with ulcerative colitis who have achieved mucosal healing

    European journal of gastroenterology & hepatology, Vol. 33, Núm. 1S Suppl 1, pp. e796-e802

2020

  1. Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease

    European Journal of Gastroenterology and Hepatology, Vol. 32, Núm. 5, pp. 588-596

2019

  1. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

    Therapeutic Advances in Gastroenterology, Vol. 12

  2. Cases report: Severe colonic bleeding in ulcerative colitis is refractory to selective transcatheter arterial embolization

    BMC Gastroenterology, Vol. 19, Núm. 1

  3. Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease

    Therapeutic Advances in Gastroenterology, Vol. 12

  4. Genetic predictors of long-term response and trough levels of infliximab in crohn's disease

    Pharmacological Research, Vol. 149

  5. Metabolic bone disease in patients diagnosed with inflammatory bowel disease from Spain

    Therapeutic Advances in Gastroenterology, Vol. 12

2015

  1. A new role for reticulon-4B/NOGO-B in the intestinal epithelial barrier function and inflammatory bowel disease

    American Journal of Physiology - Gastrointestinal and Liver Physiology, Vol. 308, Núm. 12, pp. 981-993

  2. Incidence, management, and course of cancer in patients with inflammatory bowel disease

    Journal of Crohn's and Colitis, Vol. 9, Núm. 4, pp. 326-333

  3. Lipid Profile in Inflammatory Bowel Disease Patients on Anti-TNFα Therapy

    Digestive Diseases and Sciences, Vol. 60, Núm. 7, pp. 2130-2135

  4. Safety and Efficacy of Anti-TNFα Treatment in Crohn's Disease Patients with Abdominal Abscesses

    Hepato-gastroenterology, Vol. 62, Núm. 139, pp. 647-652

2014

  1. Listeria monocytogenes infection in inflammatory bowel disease patients: Case series and review of the literature

    European Journal of Gastroenterology and Hepatology, Vol. 26, Núm. 11, pp. 1247-1252

  2. Prospective study of BK virus infection in patients with inflammatory bowel disease

    The Scientific World Journal, Vol. 2014